Sanjay Chanda - 20 Feb 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Development Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Issuer symbol
ANTX
Transactions as of
20 Feb 2026
Net transactions value
$0
Form type
4
Filing time
23 Feb 2026, 16:35:02 UTC
Previous filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chanda Sanjay Chief Development Officer C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK /s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda 23 Feb 2026 0001571820

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +38,000 +47% $0.000000 118,823 20 Feb 2026 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +77,000 $0.000000 77,000 20 Feb 2026 Common Stock 77,000 $1.04 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
F2 Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.
F3 Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.
F4 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Remarks:

Exhibits: